Trial Profile

An Open-label, Phase I Dose Escalation Followed by Dose Expansion Trial in Patients With Advanced Solid Tumours to Investigate Safety, Pharmacokinetics, and Efficacy and to Select the Dose for Further Development of BI 770371 in Combination With Ezabenlimab

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 02 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BI 770371 (Primary) ; Ezabenlimab (Primary)
Indications Colorectal cancer; Ovarian cancer; Prostate cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Boehringer Ingelheim

28 May 2025 Planned End Date changed from 30 Sep 2025 to 30 Sep 2026.
22 May 2025 Results presented in a Boehringer Ingelheim Media Release.
23 Apr 2025 According to a OSE Immunotherapeutics media release, company will present data from this study in an oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 1-5, 2025, in Chicago, Illinois.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com